Loading patent…
OwnerNicolae GRIGORE, Laurent PONS +2inventors
InventorsNicolae GRIGORE, Laurent PONS, Katie RUFFLE, Philippe PICAUT
Estimating the term…
The present invention provides a modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT/A is administered by way of a unit dose of greater than 1754 pg or greater than 8000 pg) of modified BoNT/A per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT/A administered during the treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN domain), and a BoNT/B receptor binding domain (HC domain).
A modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject,
A modified BoNT/A for use in treating facial lines, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject,
The modified BoNT/A for use according to any one of the preceding claims, wherein the unit dose is greater than 8000 pg and up to 15,000 pg of modified BoNT/A.
The modified BoNT/A for use according to any one of the preceding claims, wherein the unit dose of modified BoNT/A is greater than 8000 pg and wherein the unit dose of modified BoNT/A is up to 11,000 pg of modified BoNT/A.
The modified BoNT/A for use according to any one of the preceding claims, wherein the unit dose of modified BoNT/A is greater than 8000 pg and wherein the unit dose of modified BoNT/A is up to 10,000 pg of modified BoNT/A.
The modified BoNT/A for use according to any one of the preceding claims, wherein the total dose of modified BoNT/A administered during the treatment is up to 240,000 pg.
The modified BoNT/A for use according to any one of the preceding claims, wherein the modified BoNT/A has a Safety Ratio of greater than 7, wherein the Safety Ratio is calculated as:
The modified BoNT/A for use according to any one of the preceding claims, wherein the modified BoNT/A is for use in treating glabellar lines, preferably wherein said modified BoNT/A is administered at two sites of a corrugator muscle and one site of a procerus muscle, more preferably wherein said modified BoNT/A is administered at a total of five sites (e.g. two sites of a corrugator muscle per eye, and one site of a procerus muscle).
The modified BoNT/A for use according to any one of the preceding claims, wherein the modified BoNT/A is for use in treating glabellar lines, preferably wherein said modified BoNT/A is administered at two sites per corrugator muscle and one site of a procerus muscle, more preferably wherein said modified BoNT/A is administered at a total of five sites (e.g. two sites of a corrugator muscle per eye, and one site of a procerus muscle).
The modified BoNT/A for use according to any one of the preceding claims, wherein said modified BoNT/A is administered to 5, 6, 10, 11 or 16 sites (preferably to a maximum of 5, 6, 10, 11 or 16 site;
The modified BoNT/A for use according to any one of the preceding claims, wherein said modified BoNT/A is administered to 7, 9, 11, 13 or 15 sites;
The modified BoNT/A for use according to any one of the preceding claims, wherein the modified BoNT/A comprises a polypeptide sequence having at least 70%, 75%, 80%, 85%, 90% or 95% sequence identity to SEQ ID NO:
A unit dosage form of modified botulinum neurotoxin A (BoNT/A), the unit dosage form comprising:
Dependencies are inferred from the claim text.